Harmony Biosciences Sign Pact with Bioprojet To Develop TPM 1116

India Pharma Outlook Team | Monday, 15 April 2024

 oral orexin-2, clinical need, India Pharma Outlook

Harmony Biosciences, a dedicated firm in creating and conveying medicines for uncommon neurological sicknesses, has declared a licensing contract with Bioprojet to create, make and popularize TPM-1116, an exceptionally strong and specific oral orexin-2 receptor (OX2R) agonist that will be assessed for the therapy of narcolepsy and other rest/wake issues.  

Narcolepsy and other hypersomnolence messes keep on being an enormous market, a valuable open door with huge neglected clinical need. This understanding will speed up the advancement of this orexin-2 receptor agonist. It is supposed to add Harmony's leadership in the rest/wake space, supporting its obligation to progress creative therapies for patients living with neglected clinical requirements, as per Jeffrey M. Dayno, CEO.

"Orexin agonism is an exciting area of sleep disorder research and represents the next novel mechanism of action for the treatment of narcolepsy since the launch of Wakix. We also see potential synergies between TPM-1116 and our lead product, Wakix, and new formulations of pitolisant, because of the interplay between histamine and orexin in the hypothalamus," Dayno said. "We believe TPM-1116, a new chemical series of orexin 2 agonist, could emerge with a potential best-in-class clinical profile based on its potency and selectivity, along with its strong preclinical safety profile and potential for once daily dosing. We look forward to working with Bioprojet and advancing the development program for TPM-1116 as part of our growth strategy."

"We are pleased that this new project to develop a potentially best-in-class orexin-2 receptor agonist will extend the productive collaboration between Bioprojet and Harmony in the field of sleep medicine beyond the successful commercialization of Wakix in narcolepsy and the discovery of novel formulations of pitolisant to extend the pitolisant franchise," said Professor Jean-Charles Schwartz, co-founder of Bioprojet and member of the French and European Academies of Science.